Hepatitis C virus related cirrhosis decreased as indication to liver transplantation since the introduction of direct-acting antivirals: A single-center study

Table 4 Characteristics of hepatitis C virus patients at liver transplantation before and after direct-acting antiviral introduction, according to indication to waiting list registration (decompensated liver disease or hepatocellular carcinoma) n (%)

	dec-HCV			HCV/HCC
	Pre-DAA n = 91	Post-DAA n = 51	P value	Pre-DAA n = 89	Post-DAA n = 58	P value
Gender (male)	74 (81)	40 (78.4)	ns	77 (86.5)	49 (84.5)	ns
Age (yr)	54.8 ± 8	56 ± 8	ns	57 ± 7	58 ± 7	ns
Refractory ascites (yes)	37 (40.6)	27 (53)	ns	-	-
Blood group			ns			ns
0	41 (45)	21 (41.7)		37 (41.5)	19 (32.7)
A	35 (38)	22 (43.3)		39 (43.8)	28 (54.9)
AB	3 (3.3)	3 (5.8)		4 (4.5)	2 (3.4)
B	12 (13)	5 (9.8)		9 (10.2)	9 (15.5)
HCC (yes)	19 (20.8)	19 (37.3)	0.04	-	-
Child-Pugh classes			ns			0.001
A	3 (3.2)	1 (1.9)		38 (42.6)	42 (72.4)
B	27 (29.6)	17 (33.3)		42 (47.2)	12 (20.6)
C	61 (67.1)	33 (64.7)		9 (10)	4 (6.8)
MELD at LT	24 ± 6.5	23 ± 7.5	ns	11.7 ± 4	11.2 ± 3	ns
SVR at time of LT (yes)	8 (8.8)	15 (29.4)	0.002	10 (11)	24 (41)	0.0001
SVR after IFN-based regimens	7 (7.6)	2 (3.9)		9 (10.1)	1 (1.7)
Waiting time (mo)	8.3 ± 12	10.6 ± 12	ns	9 ± 7.7	10 ± 11	ns

HCV: Hepatitis C virus; HCC: Hepatocellular carcinoma; DAA: Direct-acting antivirals; BMI: Body mass index; MELD: Model of End-Stage Liver Disease; LT: Liver transplantation; SVR: Sustained virological response.